BMJ Open (Jun 2024)

Effect of intraocular pressure reduction on progressive high myopia (PHM study): study protocol of a randomised controlled trial

  • Jost B Jonas,
  • Wei Wang,
  • Kyoko Ohno-Matsui,
  • Tin Aung,
  • Ching-Yu Cheng,
  • Ling Jin,
  • Mingguang He,
  • Ki Ho Park,
  • Fei Li,
  • Kai Gao,
  • Xiulan Zhang,
  • Zhenyu Wang,
  • David Friedman,
  • Neil M Bressler,
  • Yizhi Liu,
  • Xiang Chen,
  • Guangxian Tang,
  • Lin Lv,
  • Jingwen Jiang,
  • Yunhe Song,
  • Fengbin Lin,
  • Shida Chen,
  • Meiling Chen,
  • DENNIS S C LAM,
  • Paul Healey,
  • Yuhong Liu,
  • Linda M. Zangwill,
  • Xinbo Gao,
  • Fengqi Zhou,
  • Tingting Lin,
  • Kangjie Kong,
  • Peiyuan Wang,
  • Jinmei Chen

DOI
https://doi.org/10.1136/bmjopen-2024-084068
Journal volume & issue
Vol. 14, no. 6

Abstract

Read online

Background In adult patients with high myopia (HM), progressive axial elongation poses a significant risk for the development of subsequent ocular complications that may lead to visual impairment. Effective strategies to reduce or prevent further axial elongation in highly myopic adult patients have not been available so far. Recent studies suggested that medically lowering intraocular pressure (IOP) may reduce axial elongation.Objective This clinical randomised controlled trial (RCT) aims to evaluate the efficacy of medical IOP reduction in adult patients with progressive HM (PHM).Trial design Single-centre, open-label, prospective RCT.Methods This RCT will recruit 152 participants with PHM at the Zhongshan Ophthalmic Center (ZOC). Randomised in a ratio of 1:1, participants will receive IOP-lowering eyedrops (intervention group) or will be followed without treatment (control group) for 12 months. Follow-up visits will be conducted at 1, 6 and 12 months after baseline. Only one eye per eligible participant will be included for analysis. The primary outcome is the change in axial length (AL) within the study period of 12 months. Secondary outcomes include the incidence and progression of visual field (VF) defects, changes in optic disc morphology and incidence and progression of myopic maculopathy. Difference in AL changes between the two groups will be analysed using linear regression analysis. For the secondary outcomes, a multifactor Poisson regression within a generalised linear model will be used to estimate the relative risk of progression in VF defects and myopic maculopathy, and the rate of thinning in retinal nerve fibre layer and ganglion cell-inner plexiform will be assessed through Kaplan-Meier curves and log-rank tests.Ethics and dissemination Full ethics approval for this trial has been obtained from the Ethics Committee of ZOC, Sun Yat-sen University, China (ID: 2023KYPJ110). Results of this trial will be disseminated through peer-reviewed journals and conference presentations.Trial registration number NCT05850936.